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Abstract
Background:	Propionate	exhibits	affinity	 for	 free	 fatty	acid	 receptor	2	 (FFA2,	 for‐
merly	GPR43)	and	FFA3	(GPR41).	These	two	G	protein‐coupled	receptors	(GPCRs)	
are	expressed	by	enteroendocrine	L	cells	 that	contain	anorectic	peptide	YY	 (PYY)	
and	glucagon‐like	peptide	1	(GLP‐1),	while	FFA3	is	also	expressed	by	enteric	neurons.	
Few	studies	have	investigated	the	individual	roles	of	FFA2	and	FFA3	in	propionate’s	
gastrointestinal	 (GI)	 effects.	Here,	we	compared	FFA2,	FFA3,	 and	propionate	mu‐
cosal	responses	utilizing	selective	ligands	including	an	FFA3	antagonist,	in	mouse	and	
human colonic mucosa.
Methods:	Vectorial	ion	transport	was	measured	in	native	colonic	preparations	from	nor‐
mal mouse and human colon with intact submucosal innervation. Endogenous fecal pel‐
let	propulsion	was	monitored	in	colons	isolated	from	wild‐type	(WT)	and	PYY−/−	mice.
Key Results:	FFA2	and	FFA3	signaling	differed	significantly.	FFA2	agonism	involved	
endogenous	L	cell‐derived	PYY	and	was	glucose	dependent,	while	FFA3	agonism	was	
independent	of	PYY	and	glucose,	but	required	submucosal	enteric	neurons	for	activ‐
ity.	 Tonic	 FFA3	 activity	was	 observed	 in	mouse	 and	 human	 colon	mucosa.	Apical	
propionate	 responses	were	a	combination	of	FFA2‐PYY	mediation	and	FFA3	neu‐
ronal GLP‐1‐ and CGRP‐dependent signaling in mouse ascending colon mucosa. 
Propionate	also	slowed	WT	and	PYY−/−	colonic	transit,	and	this	effect	was	blocked	
by a GLP‐1 receptor antagonist.
Conclusions & Inferences:	We	conclude	that	luminal	propionate	costimulates	FFA2	
and	FFA3	pathways,	reducing	anion	secretion	and	slowing	colonic	motility;	FFA2	via	
PYY	mediation	and	FFA3	signaling	by	activation	of	enteric	sensory	neurons.
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1  | INTRODUC TION
The beneficial effects of dietary fiber are partially due to its microbial 
metabolism	into	the	short‐chain	fatty	acids	(SCFAs)	such	as	acetate	
and butyrate, with propionate accounting for ~25% of these fermen‐
tation products.1 Intracolonic infusion of propionate stimulates the 
corelease	of	glucagon‐like	peptide‐1	(GLP‐1)	and	peptide	YY	(PYY)	in	
rodents2,3 and man,4 promoting energy metabolism,5 and preventing 
weight gain in overweight subjects.6	 SCFAs	also	exhibit	 a	 range	of	
gastrointestinal (GI) activities that include epithelial barrier mainte‐
nance,7 altered motility,8‒11 and epithelial ion transport12‒14 that in‐
volve	PYY	and	GLP‐1,15,16 while butyrate is additionally (and uniquely 
among	SCFAs)	an	energy	source	for	enterocytes.	SCFAs	activate	sev‐
eral G protein‐coupled receptors (GPCRs) whose functional signifi‐
cance remains obscure primarily because of a lack of selective ligands. 
GI	mucosal	signaling	is	further	complicated	by	the	presence	of	SCFA	
transporters that readily absorb these anions.14 Nevertheless, studies 
utilizing selective antagonists and agonists have enabled some reso‐
lution	of	two	GPCRs,	namely	free	fatty	acid	2	(FFA2;	formerly	GPR43)	
and	 FFA3	 (GPR41).15‒17	 In	 GI	mucosae,	 FFA2	 and	 FFA3	 responses	
appear to be Gαq linked in L cells
15,16 while Gαi/o coupling mediates 
FFA2‐induced	ghrelin	secretion.18 Propionate exhibits a similar affin‐
ity	for	FFA2	and	FFA3	(as	does	acetate),	but	butyrate	preferentially	
binds	FFA3	and	another	receptor,	GPR109A	(also	known	as	HCA2).19 
Notably,	FFA2	and	FFA3	GI	expression	patterns	differ.	 In	the	distal	
small	 intestine	 and	 colon,	 FFA2	 is	 expressed	 predominantly	 by	 L	
cells	(that	contain	PYY	and	GLP‐1),	submucosal	leukocytes,	and	mast	
cells,16,20	while	FFA3	 is	expressed	 in	L	cells	 and	enteric	neurons	 in	
both myenteric and submucosal ganglia.16
Selective	 FFA2	 or	 FFA3	 ligands	 have	 become	 commercially	
available21‒23	and	revealed	discrete	functions	for	FFA215,16,24 and 
FFA3.16,25	Using	a	selective	FFA2	agonist	 (named	Compound	1),	
we	 showed	 that	FFA2	agonism	 induced	PYY,	 rather	 than	GLP‐1	
activity in mouse colonic mucosa, activating anorexigenic path‐
ways without improving glucose tolerance in vivo in lean or obese 
mice.24 The majority of L cell vesicles contain one or the other 
peptide;26 thus, independent release is possible but has not been 
a	common	observation	to	date.	In	fact,	this	selective	FFA2	agonist	
suppressed	insulin	levels	in	vivo,	so	we	concluded	that	FFA2	could	
be a therapeutic target for obesity rather than type 2 diabetes.24 
In	contrast,	FFA3	signaling	appears	to	be	primarily	neural16,27 and 
in the GI tract may involve cholinergic nicotinic (in the rat as‐
cending colon17) and 5‐hydroxytryptamine (5‐HT) mechanisms27 
and	 possibly	 vasoactive	 intestinal	 polypeptide	 (VIP16), although 
FFA3	expression	has	also	been	observed	in	human	colon	epithe‐
lia.28	 Species	 variations	 in	 the	 signaling	 bias	 of	 FFA2	 and	 FFA3	
agonists have presented significant challenges for their transla‐
tion.23	Mindful	of	this	challenge	and	the	availability	of	selective	
agonists,	our	primary	aim	was	 to	 test	 the	hypothesis	 that	FFA3	
signaling	was	predominantly	neuronal,	while	FFA2	signaling	was	
not	neuronally	mediated,	and	propionate	was	a	coagonist	at	FFA2	
and	FFA3.		The	FFA3	antagonist,	AR399519	(alongside	the	FFA3	
agonist, AR42062618)	was	used	to	assess	the	involvement	of	FFA3	
in propionate responses. Additionally, the regional sensitivity to 
AR420626 was established in mouse GI tract and, importantly, in 
human	 colonic	mucosa	 and	 the	 endogenous	mediators	 of	 FFA3	
mucosal	 signaling	 were	 compared	 with	 FFA2	 enteroendocrine	
signaling in mouse mucosae.3,15,24
2  | MATERIAL S AND METHODS
2.1 | Materials
BIBO3304, BIIE0246, BIBN4096, and phloridzin were purchased 
from	Tocris	 (Bristol,	UK).	 Stock	 solutions	 of	BIBO3304,	BIIE0246,	
and	BIBN4096	were	 dissolved	 in	 10%	dimethyl	 sulfoxide	 (DMSO,	
at 1 m mol L−1)	 and	 were	 stored	 at	 −20°C.	 The	 FFA2	 agonist,	 PA	
was	 purchased	 from	 Calbiochem	 (Watford,	 UK),	 peptides	 were	
from	 Cambridge	 Bioscience	 (Cambridge,	 UK)	 and	 stock	 aliquots	
were	 stored	 at	 −20°C,	 undergoing	 one	 freeze‐thaw	 cycle	 only.	
Tetrodotoxin	 (TTX)	was	purchased	from	Abcam	 (Cambridge)	while	
all	 other	 agents,	 including	 sodium	 propionate,	 were	 from	 Sigma	
(Poole,	UK).
K E Y W O R D S
enteric	submucosal	neurons,	enteroendocrine	L	cells,	FFA2	and	FFA3,	human	colon,	mouse	
colon, propionate
Key Points
•	 Short	chain	fatty	acid	(SCFA)	receptors,	FFA2	and	FFA3,	
are	expressed	by	enteroendocrine	cells,	with	FFA3	also	
on	enteric	neurons.	Selective	ligands	for	these	receptors	
have	 recently	 become	 available.	 We	 compared	 FFA2	
and	FFA3	agonism	and	propionate	responses	in	gastro‐
intestinal mucosae. 
•	 FFA3	 signaling	 involved	 enteric	 neurons	 and	 was	 glu‐
cose	 independent,	 whereas	 FFA2	 signaling	 involved	
PYY	 and	 was	 mucosal	 derived.	 Luminal	 propionate	
costimulated	FFA2	and	FFA3	signaling	and	slowed	co‐
lonic transit.
•	 SCFAs	coactivate	enteric	mucosal	hormone	and	neural	
pathways to modulate gut functions.
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2.2 | Methods
2.2.1 | Mucosal ion transport (short‐circuit current; 
Isc) in vitro
All	mice	with	the	C57BL/6‐129/SvJ	background	strain	had	free	ac‐
cess to standard chow and water. Animals were housed under con‐
trolled conditions (12:12 hours light/dark cycle, lights on 07.00 hours, 
22	±	2°C)	and	their	care	and	experimental	procedures	complied	with	
the	Animals	(Scientific	procedures)	Act	1986.
Mucosal	 preparations	 (0.14	cm2 exposed areas) were dis‐
sected as described previously29 and were devoid of overlying 
smooth muscle and myenteric plexi but retained intact submuco‐
sal innervation. In tissue surveys, two adjacent pieces of mucosae 
from designated GI areas, that is, duodenum, jejunum, terminal 
ileum, ascending colon (next to the cecal junction, identified as 
AC1‐AC2), or descending colon (DC2‐DC1, the latter adjacent to 
the rectum30)	were	prepared	from	either	wild‐type	(WT;	PYY+/+)	
or	 PYY	 knockout	 (PYY−/−)	 mice	 and	 bathed	 in	 Krebs‐Henseleit	
buffer	(KH;	in	m	mol	L−1:	NaCl	118,	KCl	4.7,	NaHCO3	25,	KH2PO4 
1.2,	MgSO4 1.2, CaCl2	2.5,	D‐glucose	11.1,	pH	7.4).	Mucosae	were	
voltage	clamped	at	0	mV	in	Ussing	chambers24,29,30 and the resul‐
tant short‐circuit current (Isc) was allowed to stabilize before drug 
addition, recording maximum changes in Isc as μA/cm2.	The	FFA2	
and	FFA3	agonists	(PA;	named	compound	58	in	Wang	et		al31 and 
AR420626,	respectively),	FFA3	antagonist	AR399519	(abbreviated	
to AR19 in18),	 or	 the	SCFA,	propionate	 (5	n	mol	 L−1) were added 
apically unless otherwise stated, while all peptides, other antago‐
nists,	and	TTX	(100	n	mol	L−1) were added basolaterally. In studies 
comparing ascending and descending colonic mucosae, no more 
than four adjacent sections were prepared from the most prox‐
imal or distal regions, respectively. Addition of PA, AR420626, 
or	 propionate	 occurred	 5‐10	minutes	 after	 VIP	 (10	 or	 30	n	mol	
L−1;	unless	otherwise	stated)	while	PYY	(10	n	mol	L−1) or exendin 
4 (100 n mol L−1) responses were obtained at least 25 minutes 
after	the	FFA2/FFA3	ligands.	Endogenous	PYY,	GLP‐1,	calcitonin	
gene‐related peptide (CGRP), acetylcholine (ACh), or 5‐HT media‐
tion	of	FFA2	or	FFA3	activities	were	determined	using	optimized	
pretreatments	with	selective	antagonists,	that	is,	the	Y1	antago‐
nist	(BIBO3304,	BIBO;	300	nM)	±	Y2	antagonist	(BIIE0246,	BIIE;	
1	µM)	±	GLP‐1	antagonist	(exendin(9‐39),	Ex(9‐39);	1	µ	mol	L−1), or 
the CGRP antagonist BIBN4096 (10 n mol L−1 or 1 µ mol L−1, for 
ascending or descending colon mucosae30), atropine (1 µ mol L−1), 
hexamethonium (200 µ mol L−1), or the 5‐HT4	antagonist	RS39604	
(1 µ mol L−1).	 After	VIP,	 FFA2	 and	 FFA3	 agonist	 responses	were	
monophasic reductions in Isc, while propionate initiated biphasic 
changes in Isc; an initial transient increase in Isc (denoted as the 
1˚	 component)	 was	 followed	 by	 a	 slower	 secondary	 (2˚)	 longer	
lasting reduction in Isc. These Isc response components were an‐
alyzed separately.
In glucose sensitivity studies, the colonic mucosae were bathed 
with	 KH	 containing	 glucose	 (11.1	m	mol	 L−1) on the basolateral 
side, but mannitol (11.1 m mol L−1) replaced glucose in the apical 
reservoir,24	and	apical	FFA3	agonist	or	propionate	responses	were	
recorded subsequently. As a control, blockade of the Na+‐glu‐
cose	 cotransporter	 1	 (SGLT1)	was	 achieved	with	 apical	 phloridzin	
(50 µ mol L−1), which reduced Isc levels, but only in the presence of 
apical glucose.
2.2.2 | Human colonic mucosal studies
Colonic specimens were obtained from patients undergoing elective 
surgery for colonic cancer. Informed consent was obtained from four 
patients (two males, two females, mean age 53.5 ± 2.0 year) with 
ethical	approval	from	the	Guy’s	and	St	Thomas’	Hospitals	Research	
Ethics	 Committee.	 Mucosae	 were	 prepared	 as	 described	 previ‐
ously32,33 and experimental protocols were the same as those de‐
scribed	for	murine	mucosae	but	without	VIP	pretreatment.	Based	on	
the maximal responses recorded in mouse mucosae, concentrations 
of 1 µ mol L−1 for AR399519 and 3 µ mol L−1 for AR420626 (apically) 
followed by 100 n mol L−1	PYY	 (basolateral)	were	added	 to	human	
colon mucosal preparations.
2.2.3 | Endogenous fecal pellet propulsion 
measurement in mouse colon in vitro
Colonic transit of endogenous fecal pellets was measured in vitro 
by incubating colons (from the caeco‐colonic junction to the rec‐
tum)	 from	WT	or	PYY−/−	mice	 for	20	minutes	 in	KH	buffer	con‐
taining vehicle (H2O	or	0.1%	DMSO),	PA	or	AR420626	 (either	at	
1 µ mol L−1), or propionate (5 m mol L−1). Pellet propulsion was 
assessed by taking photographs at t = 0 and t = 20 min, measur‐
ing the mean pellet movement relative to the total colonic length 
(quoted as a % of colonic transit), as described previously.29	Where	
colons were pretreated with the GLP‐1 antagonist, Ex(9‐39) fecal 
pellet positions were measured at t = 0 and t = 20, to measure the 
effect of GLP‐1 blockade, following which propionate was added 
to	the	KH	and	transit	measured	after	a	further	20	minutes	(t = 40), 
with control tissues substituting vehicle (H2O) for the antagonist. 
In the rare event that a pellet was excreted during drug incuba‐
tion	periods,	then	that	pellet’s	movement	was	excluded	from	the	
pooled data.
2.2.4 | Data analysis
All	 data	 are	 presented	 as	 means	±	1SEM.	 Analyses	 were	 per‐
formed	 using	 GraphPad	 Prism	 v7.03,	 by	 Student’s	 t test or 
one‐way	ANOVA	with	Dunnett’s	 or	 Bonferroni’s	multiple	 com‐
parison	post	hoc	tests,	as	appropriate.	When	comparing	the	ef‐
fect of a pretreatment or the presence/absence of glucose in 
an adjacent mucosal preparation, the control and experimental 
agonist	 responses	were	compared	using	Student’s	 t test.	When	
more than one pretreatment was compared (eg, after different 
antagonists	but	using	 the	 same	agonist),	 then	one‐way	ANOVA	
with	 Dunnett’s	 posttest	 was	 applied.	 P	≤	0.05	 was	 statistically	 
significant.
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3  | RESULTS
3.1 | Mucosal FFA3 agonism involves submucosal 
neurons, not PYY mechanisms as observed for FFA2 
agonism
FFA3	activity	was	monitored	using	the	selective	agonist,	AR420626.	
When	added	apically	(after	VIP),	AR420626	elicited	monophasic	re‐
ductions	 in	 Isc	 (Figure	1A)	 in	mucosal	preparations	 from	the	small	
and	large	intestine	(Figure	1B).	The	greatest	FFA3	efficacy	was	ob‐
served in distal regions (terminal ileum, ascending, and descending 
colon)	in	contrast	with	more	uniform	FFA2	signaling	(using	the	com‐
mercially available agonist, PA; 100 n mol L−1	apically,	Supporting	in‐
formation	Figure	S1A,	B).	In	the	descending	colon,	apical	AR420626	
responses were concentration dependent, exhibiting an EC50 value 
of 22.6 n mol L−1 (11.3‐45.2 n mol L−1) and responses to basolat‐
eral AR420626 (1 µ mol L−1) were identical to apical responses 
(Figure	1C).	Apical	PA	concentration‐responses	exhibited	an	EC50 of 
29.5 n mol L−1 (8.8‐94.5 n mol L−1)	in	the	ascending	colon	(Supporting	
information	 Figure	 S1C)	 and	 5.4	n	mol	 L−1 (2.1‐14.2 n mol L−1) in 
the	 descending	 colon	 (Supporting	 information	 Figure	 S1D).	 FFA2	
mucosal	 signaling	 (Supporting	 information	 Figure	 S1E,	 F)	 differed	
significantly	 from	 FFA3	 agonism.	 The	 latter	was	 abolished	 by	 the	
neurotoxin	TTX	but	was	unaffected	by	pretreatment	with	PYY‐Y1	
and	Y2	antagonists,	in	ascending	and	descending	colon	(Figure	1D).	
This	 indicates	 a	 submucosal	 neuron‐dependent,	 PYY‐independent	
FFA3	mechanism,	while	FFA2	responses	were	PYY‐Y1/Y2	mediated	
F I G U R E  1  The	effect	of	apical	FFA3	agonist	AR420626	(100	n	mol	L−1)	on	VIP	pretreated	mouse	descending	colon	mucosa	(A)	and	in	(B)	
a	comparison	of	mucosal	AR420626	responses	in	the	duodenum	(Duod),	jejunum	(Jej),	terminal	ileum	(T.	Ileum),	ascending	colon	(A.	Colon),	
and descending colon (D. Colon). C, A concentration‐response relationship for AR420626 (constructed from single apical additions only) 
compared with 1 µ mol L−1	AR420626	added	basolaterally	(open	triangle)	in	the	mouse	D.	colon.	D,	Attenuation	of	apical	FFA3	agonism	
(1 µ mol L−1)	following	TTX	(100	n	mol	L−1)	pretreatment	but	not	Y1/Y2	blockade	with	BIBO3304	and	BIIE0246	(+BIBO/BIIE)	in	mouse	A.	
colon and D. colon mucosae. E, Glucose substitution with mannitol, either basolaterally (Bl) or apically (Ap), had no significant effect on 
murine	FFA3	responses,	whereas	apical	mannitol	prevented	the	effects	of	SGLT1	inhibitor,	phloridzin	(Phlor,	50	µ	mol	L−1).	F,	Apical	FFA3	
responses (AR420626, 3 µ mol L−1)	in	naive	human	colon	mucosa	exhibited	sensitivity	to	TTX,	but	not	to	Y1/Y2	antagonism	(BIBO/BIIE).	
Values	are	the	mean	±	1SEM	from	3‐7	observations	and	statistical	differences	between	control	and	experimental	groups	are	as	shown	
(*P ≤	0.05,	**P ≤	0.01,	***P ≤	0.001)
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and	not	neuronal	 in	 the	 same	colonic	 regions.	TTX	alone	 reduced	
basal Isc levels (data not shown) indicating the presence of a neuro‐
genic secretory tone, as observed previously in mouse and human 
colon.29,33
Previous	 studies	 have	 revealed	 that	 FFA2‐induced	 GLP‐1	 and	
PYY	release	from	murine	L	cells	was	glucose	dependent.15,24 In con‐
trast,	 we	 found	 that	 FFA3	 responses	 were	 insensitive	 to	 glucose	
substitution	 with	 mannitol	 on	 either	 mucosal	 surface	 (Figure	 1E).	
Predictably, the internal control, phloridzin was only effective when 
apical glucose was present, representing the blockade of this absorp‐
tive Na+‐linked	mechanism	(Figure	1E).	Notably,	AR420626	mucosal	
responses in human colon mucosa were also monophasic reductions 
in	 Isc	and	this	activity	was	TTX	sensitive,	and	Y1/Y2	 independent	
(Figure	1F),	demonstrating	conserved	FFA3	mechanisms	 in	human	
and mouse colonic mucosae.
FFA3	 agonism	 has	 been	 shown	 to	 inhibit	 cholinergic	 neuro‐
transmission in rat colon mucosa17 while in mouse small intes‐
tine,	FFA3	is	colocalized	with	VIP	in	neurons	located	within	both	
the submucosal and myenteric plexi.16	We	 set	 out	 to	 ascertain	
which	neurotransmitters	predominantly	mediate	FFA3	responses	
but	 could	not	pursue	VIP‐specific	mechanisms,	 as	 in	our	hands,	
none	 of	 the	 commercially	 available	 antagonists	 block	 VPAC	 re‐
sponses	(Cox	et		al.	unpublished	findings).	We	therefore	focussed	
on cholinergic mechanisms utilizing the muscarinic antagonist, 
atropine, or nicotinic blocker hexamethonium, which revealed a 
significant nicotinic tone that was greater in the ascending than 
the	 descending	 colon	mucosa	 (Figure	 2A).	Only	 in	 the	 proximal	
colon,	 hexamethonium	 significantly	 inhibited	 the	 2˚	 (antisecre‐
tory)	FFA3	activity	of	AR420626	(Figure	2B).	Muscarinic	blockade	
had no effect on either component of the AR420626 response, al‐
though atropine abolished subsequent carbachol (CCh) responses 
(data	not	shown)	in	both	regions.	We	have	previously	shown	that	
CGRP is coexpressed in cholinergic submucosal neurons in the 
mouse colon34 and so the CGRP antagonist, BIBN4096 was uti‐
lized (at the optimal concentrations previously shown to block 
CGRP activity).30	Significant	but	different	net	CGRP	tonic	activity	
was observed in proximal versus distal colon, as seen previously30 
(Figure	 2C).	 In	 vehicle‐treated	 ascending	 colon,	 AR420626	mu‐
cosal	 responses	 were	 clearly	 biphasic	 (a	 primary	 [1˚]	 increase	
in	 Isc	 followed	 by	 a	 secondary	 [2˚]	 Isc	 decrease	 [Figure	 2D]).	
CGRP	 antagonism	 selectively	 blocked	 the	 2˚	 component	 of	 the	
FFA3	response,	but	this	aspect	was	unaffected	in	the	descending	
colon,	revealing	mechanistic	differences	in	mucosal	FFA3	signal‐
ing within the mouse colon. Control CGRP (10 n mol L−1) or CCh 
(10 µ mol L−1) responses were selectively abolished by BIBN4096 
or hexamethonium, in both colonic regions (data not included).
3.2 | FFA3 antagonism reveals tonic FFA3 activity in 
mouse and human colonic mucosa
Competitive	FFA3	antagonism	with	AR399519	(applied	apically)	re‐
vealed	a	degree	of	tonic	FFA3	activity	that	was	antisecretory	in	the	
ascending	colon	(Figure	3A,	left	histogram)	but	prosecretory	in	the	
descending	colon	 (and	with	concentration	dependence;	Figure	3A,	
right	histogram).	In	both	colonic	regions,	FFA3	agonism	was	abolished	
by	AR399519	(Figure	3B),	while	PYY	responses	were	unaffected	by	
the	FFA3	antagonist	(data	not	shown).	Furthermore,	AR399519	had	
no	significant	effect	upon	FFA2	agonism	in	mouse	descending	colon	
(Figure	3C).	In	human	colon,	AR399519	revealed	tonic	mucosal	FFA3	
activity similar to that observed in mouse descending colon. The 
FFA3	 antagonist	 also	 abolished	 subsequent	 AR420626	 responses	
and	 it	had	no	effect	upon	PYY	 responses	 in	human	colon	mucosa	
F I G U R E  2   Pretreatment with acetylcholine (ACh) antagonists 
(atropine (Atr) or hexamethonium (Hex); A, B) or the CGRP 
antagonist	(BIBN4096	(BIBN);	C,	D)	inhibit	apical	FFA3	agonism	
in	the	mouse	ascending	colon	(AC;	LHS)	but	not	in	the	descending	
colon	(DC;	RHS).	A,	Naive	murine	mucosae	(ie,	no	VIP	addition)	
were pretreated with optimal muscarinic (Atr) or nicotinic 
antagonism (Hex) at the concentrations shown, revealing 
consistent	cholinergic	tone	(A).	Subsequent	biphasic	responses	
to apical AR420626 (in B: 100 n mol L−1,	identified	as	1˚	or	2˚	
Isc components) were compared with vehicle controls. C, CGRP 
antagonism with BIBN4096 (10 n mol L−1 or 1 µ mol L−1 in AC or DC, 
respectively30) blocked net CGRP tone that differed in murine AC 
and DC, while subsequent AR420626 (in D; 100 n mol L−1, apically) 
responses were significantly reduced in the ascending colon 
only	(LHS).	Note	the	difference	in	y	axes	in	A	&	C.	Values	are	the	
mean	±	1SEM	(from	numbers	shown	in	parentheses)	and	statistical	
differences between vehicle and experimental groups are as shown 
(*P ≤	0.05,	**P ≤	0.01,	***P ≤	0.001)
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(Figure	3D)	demonstrating	conserved	mechanisms	of	FFA3	signaling	
in mouse and human colon mucosa.
3.3 | Apical propionate responses are biphasic and 
involve endogenous GLP‐1 and PYY‐Y1 and Y2 
mechanisms in mouse colon mucosa
Having	established	 the	differences	between	FFA2	and	FFA3	mu‐
cosal	 signaling,	 we	 next	 investigated	 propionate’s	 acute	 effects,	
anticipating	a	combination	of	FFA2	and	FFA3	agonism.	This	SCFA	
(at 5 m mol L−1, apically) caused biphasic Isc changes in naive and 
VIP‐treated	preparations	from	the	ascending	colon	(see	the	repre‐
sentative	response,	inset	Figure	4A)	and	descending	colon	mucosa	
(Supporting	information	Figure	S2	A	and	B).	To	be	consistent	with	
our	FFA2	and	FFA3	studies,	we	focussed	on	apical	propionate	ad‐
ministration	and	initially	surveyed	propionate’s	responses	in	differ‐
ent GI regions. Propionate consistently evoked biphasic responses 
in	 WT	 jejunum,	 terminal	 ileum,	 ascending	 and	 descending	 colon	
mucosa,	with	significantly	larger	1˚	increases	in	Isc	in	the	ascending	
colon	(Figure	4A).	Apical	propionate	responses	were	slightly,	but	not	
significantly	larger	than	their	basolateral	counterparts	(Supporting	
information	 Figure	 S2A),	 and	 the	 biphasic	 character	 of	 propion‐
ate effects was consistent along the length of the mouse GI tract. 
Propionate signaling was more pronounced in the ascending colon 
compared	with	 descending	 colon	mucosa	 (Figure	 4A,	 Supporting	
information	Figure	S2).
The GLP‐1 antagonist, Ex(9‐39), significantly reduced the pro‐
pionate	1˚	component	in	the	ascending	colon,	but	it	had	no	effect	
on	the	significantly	smaller	1˚	component	in	the	descending	colon	
(Figure	4B).	The	Y1	and	Y2	antagonists	(BIBO3304	and	BIIE0246,	
respectively)	attenuated	the	2˚	Isc	reduction	to	propionate	in	both	
colonic	regions,	indicating	a	consistent	PYY‐Y1	and	Y2	mechanism	
for	 propionate’s	 antisecretory	 response	 (Figure	 4B).	 Subsequent	
responses	 to	 exogenous	PYY	 and	GLP‐1	 agonist	 exendin	4	were	
abolished by their respective antagonists (data not shown), as re‐
ported previously.24	PYY−/−	mucosae	exhibited	similar	loss	of	pro‐
pionate	 signaling	 (Figure	4C)	 to	 that	 seen	 in	WT	mucosa	 treated	
with	 Y1	 and	 Y2	 antagonists	 (Figure	 4B).	 Interestingly,	 both	 the	
F I G U R E  3  Apical	FFA3	antagonism	
with AR399519 (A) reduced basal Isc in 
mouse ascending colon (A. Colon) and 
raised Isc in mouse descending colon 
(D.	Colon).	B,	The	FFA3	antagonist	
attenuated	subsequent	FFA3	responses	
to apical AR420626 (100 n mol L−1) in 
both colonic regions. C, In contrast, 
FFA2	agonism	(100	n	mol	L−1 PA, apical) 
was	unaffected	by	the	FFA3	antagonist	
in	the	mouse	distal	colon.	D,	Similar	
increases in basal Isc were observed with 
antagonist, AR399519 (1 µ mol L−1, apical) 
and inhibition of subsequent AR420626 
(3 µ mol L−1) responses was observed in 
human	colon,	where	PYY	(100	n	mol	L−1) 
responses	were	unaffected.	Values	are	
the	mean	±	1SEM	from	4‐6	observations	
(as shown) and statistical differences 
between control and experimental groups 
are shown (**P ≤	0.01,	***P ≤	0.001)
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1˚	and	2˚	 responses	 to	propionate	were	 significantly	 inhibited	 in	
PYY−/−	ascending	and	descending	colon	(Figure	4C)	revealing	PYY	
as	a	mediator	of	both	aspects	of	the	SCFA	response.	Propionate’s	
1˚	 response	was	also	TTX	sensitive	 in	ascending	and	descending	
colon	 (Figure	 4D),	 highlighting	 a	 consistent	 neural	 involvement.	
The	 propionate’s	 1˚	 response	was	 also	 partially	 inhibited	 by	 the	
CGRP antagonist (BIBN4096), but this did not reach statistical sig‐
nificance	in	either	colonic	area	(Figure	4E).	Taken	together,	endog‐
enous	PYY	 appears	 to	 provide	 both	 a	 neural	 Y2	mechanism	 and	
an	epithelial	Y1	antisecretory	contribution	to	propionate’s	1˚	and	
2˚	responses,	respectively,29 while GLP‐1 (Ex(9‐39)‐sensitive) and 
possibly	also	neural	CGRP	appear	to	contribute	to	propionate’s	1˚	
response.
The	removal	of	apical	glucose	significantly	reduced	the	1˚	propi‐
onate’s	response	in	ascending	colon	and	it	also	significantly	inhibited	
the	PYY‐mediated	2˚	component	in	both	colonic	regions	(Figure	4F).	
This	glucose	sensitivity	is	most	likely	FFA2	mediated,	that	is,	L	cell	
derived,	since	selective	FFA2	agonism	in	mucosal	preparations	(with	
PA or Cpd124) is entirely glucose dependent. In contrast, propio‐
nate’s	1˚	response	in	the	descending	colon	was	glucose	independent,	
and notably, this component was not GLP‐1 mediated.
3.4 | FFA3 antagonism inhibits propionate 
responses in mouse colon mucosae
FFA3	 antagonism	 with	 AR399519	 revealed	 a	 difference	 in	 FFA3	
tonic activity in the mouse ascending versus the descending colon 
(Figure	3A).	In	further	support	of	this	observation,	the	presence	of	
AR399519	virtually	abolished	the	1˚	responses	to	propionate	in	the	
ascending	colon	(Figure	5A)	but	had	no	effect	on	the	smaller	1˚	re‐
sponse	 in	 the	descending	 colon	 (Figure	5B).	The	1˚	 component	of	
propionate’s	response	is	predominantly	neuronal	(Figure	4D),	so	we	
infer	that	FFA3	is	most	likely	to	be	present	on	submucosal	secretory	
neurons	 that	 innervate	 the	 colonic	 epithelium.	 Blockade	 of	 FFA3	
with	AR399519	also	attenuated	the	2˚	response	to	propionate,	sig‐
nificantly	so	in	the	descending	colon,	revealing	a	FFA3	contribution	
to	propionate’s	antisecretory	action,	particularly	in	the	distal	colon	
(Figure	5B).
The	 combination	 of	 FFA3	 blockade	 (with	 AR399519)	 and	 ei‐
ther	 the	 GLP‐1	 antagonist,	 Ex(9‐39),	 or	 Y1	 and	 Y2	 antagonists	
was	 tested	 to	 establish	whether	 endogenous	GLP‐1	 and/or	 PYY	
mediate	 the	 residual	 propionate	 response,	 that	 is,	 in	 a	 FFA3‐in‐
dependent manner. Ex(9‐39) did not significantly alter either the 
component	 of	 propionate’s	mucosal	 response	 in	 the	presence	of	
FFA3	blockade	in	ascending	colon	(Figure	5A).	 In	contrast,	propi‐
onate’s	2˚	antisecretory	response	was	significantly	attenuated	by	
the	combination	of	FFA3	antagonism	and	Y1	and	Y2	blockers	to‐
gether	 (Figure	5A,	B).	Therefore,	a	FFA3‐independent	but	never‐
theless	L	cell‐derived	PYY	mechanism	is	likely	to	be	present	along	
the	length	of	the	mouse	colon,	endogenous	PYY	acting	on	epithe‐
lial	Y1	and	neural	Y2	receptors	in	response	to	apical	administration	
of propionate.
The	relative	resistance	of	the	small	propionate’s	1˚	responses	
in descending colon mucosa to antagonists prompted us to in‐
vestigate these predominantly neural, glucose independent 
increases	 in	 Isc.	 Previous	 studies	 have	 shown	 that	 FFA3	 colo‐
calizes with 5‐HT‐containing enterochromaffin (EC) cells within 
the mucosa,35,36 so we utilized the 5‐HT4	 antagonist,	 RS39604	
to	 block	 endogenous	 5‐HT	 signaling.	 RS39604	 alone	 revealed	
minimal tonic 5‐HT4 activity compared with significant levels of 
PYY‐Y1/Y2	tone	(Supporting	information	Figure	S3A).	Neither	1˚	
nor	 2˚	 components	 of	 the	 apical	 propionate	 response	were	 al‐
tered by 5‐HT4	antagonism	(Supporting	information	Figure	S3B)	
while subsequent exogenous 5‐HT responses were abolished 
(Supporting	information	Figure	S3C).	As	seen	previously,	Y1	and	
Y2	antagonism	abolished	the	2˚	propionate’s	response	as	well	as	
subsequent	 exogenous	 PYY	 responses	 (Supporting	 information	
Figure	 S3D).	 Thus,	 propionate	 elicits	 a	 secretory,	 neural	 FFA3‐
mediated effect that is glucose insensitive and appears to be 5‐
HT independent.
F I G U R E  4   The biphasic primary (1o) and secondary (2o) changes 
in Isc following apical propionate (Prop; 5 m mol L−1)	after	VIP	(in	A)	
mouse	jejunum	(Jej),	terminal	ileum	(T.	Ileum),	ascending	colon	(A.	
Colon: and illustrated in the representative response [inset]) and 
descending colon (D. Colon) after pretreatment with BIBO3304 
and	BIIE0246	(+BIBO/BIIE),	or	Ex(9‐39)	or	vehicle	(in	B),	in	PYY−/−	
mice	(C)	or	TTX	or	vehicle	pretreatment	(D)	or	BIBN4096	(1	µ	mol	
L−1)	or	vehicle	(E),	and	presence/absence	of	apical	glucose	(F)	in	
the	A.	colon	and	D.	colon	mucosae	from	WT	mice.	Values	are	the	
mean	±	1SEM	from	5‐9	observations	and	statistical	differences	
between control and experimental response components are as 
shown (*P ≤	0.05,	**P ≤	0.01,	***P ≤	0.001)
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3.5 | FFA2 and FFA3 agonists slow fecal pellet 
propulsion in vitro
In	vitro	studies	have	shown	previously	that	L	cell‐derived	PYY	medi‐
ates	free	fatty	acid	receptor	FFA1	and	FFA4	activation	 in	mucosal	
preparations	and	 that	selective	FFA1	and	FFA4	agonists	also	slow	
colonic transit in vitro and in vivo.37 Having uncovered divergent 
FFA2	and	FFA3	signaling	mechanisms	 in	the	mouse	colon	mucosa,	
we	compared	FFA2	and	FFA3	modulation	of	endogenous	fecal	pellet	
propulsion	and	with	propionate’s	activity.	 Individual	FFA2	or	FFA3	
agonism	slowed	motility	significantly	in	WT	colon	to	similar	degrees	
(Figure	6A).	The	same	agonist	concentrations	also	reduced	motility	
in	PYY−/−	colon,	but	PA	(the	FFA2	agonist)	was	slightly	 less	effec‐
tive,	while	the	FFA3	antimotility	effect	was	significant	 (Figure	6B).	
Propionate also slowed pellet propulsion to a similar degree in both 
genotypes	(Figure	6C,	D),	significantly	so	in	PYY−/−	colon,	indicating	
that	PYY	is	not	the	sole	mediator	of	this	SCFA’s	antimotility	effects	
in the mouse colon.
We	 investigated	 the	 inhibitory	 effect	 of	 propionate	 in	 PYY−/−	
colon further by pretreating the colon with the GLP‐1R antagonist, 
Ex(9‐39) as GLP‐1 was considered to be the most likely mediator.15 
Ex(9‐39) per se had no effect on fecal pellet transit; however, after 
20‐minute	incubation	with	propionate,	Ex(9‐39)	blocked	the	SCFA’s	
inhibitory	effect	(Figure	7).
4  | DISCUSSION
4.1 | Differences between FFA2‐ and FFA3‐specific 
mucosal activities but common antimotility effects
Small	molecule	agonists	selective	 for	either	FFA2	or	FFA3	elicited	
monophasic antisecretory responses along the length of the mouse 
GI tract and in human colon mucosa. Their apical and basolateral 
responses exhibited similar time courses and efficacies (as observed 
previously	 for	FFA2	agonism	 in	 the	descending	colon24) indicating 
that these receptors are probably located on both epithelial do‐
mains,	that	is,	positioned	to	sense	SCFAs	in	the	gut	lumen	and	the	
lamina propria. However, given the difference between circulating 
(10‐100 µ mol L−1)	and	luminal	SCFA	levels	(50‐100	m	mol	L−1),10 it is 
likely	that	SCFAs	are	sensed	by	basolateral	receptors	as	their	affini‐
ties	for	SCFAs	are	within	the	plasma	concentration	range.19,38
Apical and basolateral propionate responses were also similar 
but	 in	contrast	with	FFA2	and	FFA3	responses,	 the	changes	 in	 Isc	
were biphasic and markedly so in the ascending colon. Other ro‐
dent studies have observed biphasic (sometimes triphasic) changes 
in Isc to apical propionate, for example, in guinea pig distal colon 
with 50 m mol L−1 propionate.39 In rat colon mucosa, propionate Isc 
responses	were	 only	 observed	 after	 apical	 SCFA	 addition	 and	 in‐
terestingly involved submucosal cholinergic neurons12 implicating 
trans epithelial movement and a basolateral mechanism reminiscent 
of	the	neural	FFA3	response	we	observed	in	the	present	study.	The	
absence of latency together with the similarity in propionate re‐
sponse kinetics supports the presence of receptors on apical and 
basolateral surfaces.
However,	 the	 cellular	 mechanisms	 of	 FFA2	 and	 FFA3	 selec‐
tive signaling and their glucose dependence differed markedly, as 
hypothesized.	 FFA2	 agonism	 involved	 L	 cell‐derived	 PYY	 and	 this	
mechanism was glucose dependent24 and enteric neuron indepen‐
dent,	while	 FFA3	 signaling	was	 glucose	 independent	 and	 involved	
submucosal cholinergic neurotransmission (nicotinic, predominantly) 
in	 combination	 with	 CGRP	 (Figure	 8).	 Notably,	 the	 neural	 FFA3	
F I G U R E  5   The biphasic changes in Isc with apical propionate 
(5 m mol L−1)	in	WT	mouse	ascending	colon	(A.	Colon	in	A)	
and	descending	colon	(D.	Colon	in	B).	Pretreatment	with	FFA3	
antagonist AR399519 alone (1 µ mol L−1) or in combination with 
Ex(9‐39) (1 µ mol L−1)	or	AR399519	and	Y1/Y2	antagonists	(+BIBO/
BIIE), compared with propionate responses after vehicle controls. 
Values	are	the	mean	±	1SEM	from	5‐6	observations	and	statistical	
differences are as shown (*P ≤	0.05,	***P ≤	0.001)
F I G U R E  6  Fecal	pellet	transit	in	WT	and	PYY‐/‐	mouse	colon	
in	vitro,	in	vehicle	controls	(0.1%	DMSO	in	A	&	B;	H2O in C & D), 
or	FFA2	agonist	PA	(1	µ	mol	L−1,	+PA),	FFA3	agonist	AR420626	
(1 µ mol L−1,	+AR),	or,	in	C	&	D,	propionate	(+Prop;	5	m	mol	L−1)‐
treated	tissue.	Values	are	the	mean	+	1SEM	(from	numbers	shown	
in parentheses) with statistical differences between drug‐treated 
and control groups as shown (*P ≤	0.05)
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activity was also observed in human colon mucosa. Nohr et  al16 
described	FFA3	expression	 in	 submucosal	VIP‐positive	neurons	of	
murine small intestine, that are likely to be secretomotor/vasodilator 
in	character.	However,	functional	confirmation	of	VIP’s	involvement	
was not possible in the present study due to the current lack of suit‐
ably	selective	VIP	receptor	antagonists	(Cox	&	Tough,	unpublished	
findings).
Previously	we	established	that	selective	FFA2	agonism	involved	
endogenous	 PYY	 antisecretory	 and	 antimotility	 responses,	 along‐
side a suppression of food intake that lead to a reduction in body 
weight	in	WT	mice,	and	these	activities	were	absent	in	FFA2−/−	mice	
or their tissues.24	We	were	 unable	 to	 detect	 significant	GLP‐1	 in‐
volvement	using	this	first‐in‐class	FFA2	agonist;	a	finding	that	was	
corroborated	using	the	commercially	available	FFA2	agonist,	PA	 in	
the	present	study.	However,	GLP‐1	release	occurs	with	FFA2	ago‐
nists	or	SCFA	administration	to	colonic	crypt	cultures	and	this	 is	a	
glucose‐dependent mechanism.3,15,16,40 In native mucosal prepara‐
tions, secreted GLP‐1 is probably inactivated rapidly24 and its sig‐
naling capacity may also be compromised by relatively low levels of 
GLP‐1	receptor	expression.	Differential	PYY	and	GLP‐1	signaling	is	
possible as the majority of resolvable L cell vesicles (observed by 
high‐resolution	confocal	microscopy)	contain	PYY	or	GLP‐126 rather 
than peptide copackaging as indicated by early ultrastructural stud‐
ies.41	Hence,	preferential	FFA2‐PYY	signaling	could	be	functionally	
significant,	and	its	amplification	by	SCFA‐enhanced	PYY	transcrip‐
tion also holds therapeutic potential.42	The	neural	FFA3	activity	that	
we observed here in mouse and human colon also differs markedly 
from	 FFA1	 and	 FFA4	 agonism,37 GPR119 activity43,44 as well as 
other	 L	 cell	 sensing	mechanisms	 that	 all	 involve	 endogenous	 PYY	
and/or GLP‐1 and require glucose.45,46 In addition to its neural ex‐
pression,	FFA3	is	to	some	extent	expressed	by	L	cells,	for	example,	
in mouse proximal colon,47	and	the	same	FFA3	agonist	that	we	used	
(AR420626,	but	 at	≥100x	 the	 concentration)	 stimulated	GLP‐1	 re‐
lease from colonic crypt preparations, although with much lower 
efficacy than propionate.16 Taken together, it appears that neither 
PYY	nor	GLP‐1	is	involved	in	acute	FFA3	activity	in	mouse	or	human	
colonic	mucosa	 and	 that	 neural	 FFA3	pathways	predominate	over	
FFA3	L	cell	signaling	in	these	native	tissues.
The	FFA3	antagonist	AR399519	revealed	a	degree	of	prosecre‐
tory tone in mouse and human distal colon. Ascending colon mucosa 
in	contrast	exhibited	antisecretory	FFA3	tone.	This	regional	differ‐
ence was also seen for CGRP tonic activity, implicating a functional 
link	 between	 FFA3	 and	 sensory	 CGRP‐mediated	 neural	 activity.	
Tonic cholinergic transmission in contrast (as revealed by nicotinic 
blockade) was consistently prosecretory in mouse colon. Both the 
CGRP	antagonist	BIBN4096	and	hexamethonium	attenuated	FFA3‐
induced	reductions	in	Isc	(the	2˚	component,	Figure	2),	significantly	
so	in	ascending	colon,	and	we	conclude	that	FFA3	agonism	involves	
submucosal CGRP and cholinergic neurotransmission in this region 
F I G U R E  7  Fecal	pellet	transit	in	PYY−/−	mouse	colon	in	vitro	
was unaffected by 20‐min incubation with 1 µ mol L−1 Ex(9‐39) 
compared with vehicle controls (H2O); however, a further 20‐min 
incubation	with	propionate	(+Prop;	5	m	mol	L−1) attenuated basal 
transit in control colons but not in Ex(9‐39) pretreated colons. 
Values	are	the	mean	+	1SEM	(from	number	shown	in	parenthesis).	
**P ≤	0.01	compared	with	control	at	20	min;	++P ≤	0.01	compared	
with	control	+Prop	at	40	min
F I G U R E  8  Working	model	showing	the	cellular	locations	
of	FFA2	and	FFA3	activated	by	lumenal	propionate	or	specific	
agonists, plus likely peptide mediators and the simplest neural 
circuitry, supported by our functional data in mouse ascending 
colon. Additionally, the mechanisms identified by Nøhr et  al16 
are	highlighted	by	asterisks	(*),	that	is,	VIP‐containing	submucosal	
neurons	and	L	cell	expression	of	FFA3,	also	subepithelial	
lymphocyte	FFA2	expression.	In	the	ascending	and	descending	
colon	of	mouse	and	human	colon,	FFA2	is	present	on	apical	
and	basolateral	L	cell	membranes,	while	FFA3	is	predominantly	
neuronal, potentially on cholinergic, CGRP‐containing submucosal 
neurons.	In	mouse	ascending	colon,	L	cell‐derived	PYY	and	
GLP‐1	partially	mediate	apical	propionate	responses,	while	PYY	
predominantly	mediates	FFA2	agonism.24
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(Figure	 8).	 Previously,	 we	 found	 that	 all	 cholinergic	 submucous	
plexus neurons contain CGRP (in the distal colon34). If these neurons 
contribute to the tonic activity we observed, then corelease ACh 
and CGRP may occur and net epithelial anion secretion would result. 
The	sensitivity	of	FFA3	agonism	to	cholinergic	and	CGRP	blockade	
is	suggestive	that	FFA3	agonists	(potentially	via	neural	FFA3‐Gi‐, or 
GIRK	coupling)	may	inhibit	sensory	submucous	neurons	causing	hy‐
perpolarization and enteric reflex inhibition that would slow motil‐
ity, as observed for AR420626 in the colon. The neural mechanisms 
involved	 in	 FFA3	 agonism	 in	mouse	 descending	 colon	were	more	
complex; nicotinic and CGRP blockers were inhibitory here, but not 
significantly	 so.	 It	 is	possible	 that	FFA3	modulation	of	 secretomo‐
tor	VIP	neurons16	also	reduces	VIP	release	and	therefore	attenuates	
VIP‐mediated	 epithelial	 hypersecretion,	 but	 selective	 VIP	 antago‐
nists are currently unavailable to test this possibility.
Maximal	FFA2	agonism	slowed	colonic	motility	and	FFA3	activa‐
tion	retarded	motility	to	a	similar	degree	in	WT	colon.	However,	the	
FFA2	 response	 lost	 significance	 in	 PYY−/−	 colon,	 in	 contrast	with	
FFA3	agonism,	which	 remained	significant.	We	conclude	 that	PYY	
contributes	more	 to	FFA2	agonism	 than	 to	FFA3’s	antimotility	 ac‐
tivity where additional neural and/or other mediator(s), for exam‐
ple, GLP‐1, may be involved. Propionate also slowed colonic motility 
as	expected,	but	this	was	not	PYY	dependent.	This	SCFA	is	known	
to retard colonic transit in mouse and rat models via a combination 
of	 PYY	 and	GLP‐1	mechanisms.3,9,11,15	We	 confirmed	 the	 involve‐
ment	 of	GLP‐1	 in	 propionate’s	 antimotility	 effect	 in	 PYY−/−	 colon	
using the GLP‐1 antagonist Ex(9‐39). Thus, propionate slows mouse 
colonic	motility	 via	 a	 combination	 of	 endogenous	 PYY	 and	GLP‐1	
mechanisms.
4.2 | Propionate coactivates FFA2 and FFA3 with 
additional electrogenic epithelial mechanisms
Mucosal	responses	to	apical	propionate	were	a	combination	of	PYY	
and GLP‐1 signaling, and this biphasic electrogenic response was 
consistent	and	contrasted	with	 the	monophasic	FFA2	or	FFA3	 re‐
sponses in the same mucosal areas. GLP‐1 predominantly mediated 
the	1˚	 component	 of	 propionate’s	 response	 in	 the	mouse	 ascend‐
ing colon. Previously, we observed that apical acetate or propionate 
induced	biphasic	 Isc	 changes	 in	WT	colon	mucosa	and	 the	 slower	
(2˚)	 antisecretory	 component	was	 absent	 from	FFA2−/−	mucosa24 
(Supporting	 information	 Data	 S1).	 In	 the	 present	 study,	 we	 con‐
firmed	that	this	2˚	aspect	was	solely	PYY	mediated	as	it	was	abol‐
ished	by	a	combination	of	Y1	and	Y2	antagonists	 in	ascending	and	
descending	colon	mucosae.	L	cell	FFA2,	therefore,	contributes	to	the	
acute	propionate	response	(Figure	8)	and	this	specific	activity	was	
glucose sensitive, in agreement with our previous study investigat‐
ing	PYY‐mediated	mechanisms,24	and	the	increased	PYY	and	GLP‐1	
release observed in vivo to a number of luminal stimuli including pro‐
pionate.48 Additionally, in the ascending colon, the GLP‐1‐mediated 
1˚	response	to	propionate	was	also	glucose	dependent.	Interestingly,	
this	1˚	propionate	response	was	abolished	by	FFA3	antagonism,	re‐
vealing	a	SCFA‐stimulated	FFA3/GLP‐1	signal	 that	was	most	 likely	
neuronal	as	TTX	also	blocked	this	activity.	Indeed,	FFA3	antagonism	
on baseline revealed antisecretory tone in the ascending colon, and 
secretory	tone	in	the	descending	colon,	highlighting	tonic	FFA3	ac‐
tivities with opposing outcomes on mucosal secretion. However, as 
selective	FFA3	agonism	did	not	elicit	an	increase	in	Isc	in	any	prepa‐
rations and we suggest that this may be because the small molecule 
is not transported across the mucosa and cannot readily access neu‐
ronal	FFA3.	FFA3	blockade	also	inhibited	the	2o propionate response 
(significantly	so	in	the	descending	colon)	as	did	Y1/Y2	antagonists,	
implicating	the	involvement	of	endogenous	PYY	in	this	glucose‐sen‐
sitive	 component.	We,	 therefore,	 conclude	 that	 the	2o propionate 
response	 is	 likely	to	be	a	combination	of	FFA2	and	FFA3	agonism.	
In	 the	descending	colon,	 the	small	1˚	 increase	 in	 Isc	 to	propionate	
was	significantly	inhibited	by	TTX	(Figure	4D)	and	blunted	in	PYY−/−	
tissue	(Figure	4C),	 indicating	a	neural	Y2	mechanism;	however,	the	
combination	of	Y1	and	Y2	blockade	was	lost	in	the	presence	of	FFA3	
blockade	indicating	that	Y2	and	FFA3	may	be	expressed	by	the	same	
neurons	 (Figure	8).	The	residual	1˚	electrogenic	response	to	apical	
propionate was not 5‐HT‐mediated despite evidence to the con‐
trary35,36 and we propose that if endogenous 5‐HT is being released 
by propionate, then this is transient and much less efficacious than 
the pharmacologically distinct peptide and neural colonic pathways 
stimulated	 by	 the	 SCFA.	 Instead,	 we	 suggest	 that	 the	 residual	 1˚	
component may be a consequence of Na+‐coupled propionate ab‐
sorption via the apical monocarboxylic acid transporter, slc5a8,49,50 
but we did not investigate this minor electrogenic response further.
Taken together, our findings provide novel functional in‐
sights	 into	 discrete	 colonic	 FFA2	 and	 FFA3‐mediated	 pathways	
coactivated acutely by luminal propionate. The data fit with the 
hypothesis	 that	 FFA3	 activity	 is	 predominantly	 neuronal	 while	
FFA2	 signaling	 is	 primarily	 L	 cell	 derived.	 The	 involvement	 of	
FFA2‐induced	 endogenous	 PYY	 and	 GLP‐1	 release48 and inhib‐
itory	 neuronal	 (FFA3)	 SCFA	 mechanisms	 potentially	 underpin	
clinical observations showing that an increase in dietary fiber or 
intracolonic	delivery	of	propionate	elevates	postprandial	PYY	and	
GLP‐1 levels, reducing energy intake and longer term weight gain 
in overweight adults,6 and promoting energy metabolism.5 Based 
on	 these	 findings,	we	 suggest	 that	 targeting	FFA2	 and	FFA3	 to‐
gether may offer additional therapeutic potential for the treatment 
of obesity and type 2 diabetes.
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